MPM Asset Management LLC Has $75.75 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

MPM Asset Management LLC lessened its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 1.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,381,062 shares of the company's stock after selling 44,722 shares during the period. Entrada Therapeutics makes up 60.9% of MPM Asset Management LLC's holdings, making the stock its largest position. MPM Asset Management LLC owned about 11.71% of Entrada Therapeutics worth $75,749,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Barclays PLC grew its holdings in shares of Entrada Therapeutics by 210.6% in the 3rd quarter. Barclays PLC now owns 45,110 shares of the company's stock worth $720,000 after acquiring an additional 30,585 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Entrada Therapeutics by 44.0% in the 4th quarter. SG Americas Securities LLC now owns 14,036 shares of the company's stock worth $243,000 after acquiring an additional 4,291 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Entrada Therapeutics in the 4th quarter worth $137,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Entrada Therapeutics by 6.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 197,127 shares of the company's stock worth $3,408,000 after acquiring an additional 11,143 shares during the last quarter. Finally, AlphaQuest LLC acquired a new position in shares of Entrada Therapeutics in the 4th quarter worth $70,000. Institutional investors own 86.39% of the company's stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Monday, March 31st.

Entrada Therapeutics Stock Performance

Shares of TRDA stock traded down $0.03 on Friday, reaching $8.09. 217,153 shares of the company's stock traded hands, compared to its average volume of 129,636. Entrada Therapeutics, Inc. has a 12-month low of $7.10 and a 12-month high of $21.79. The company has a market capitalization of $307.04 million, a P/E ratio of 5.09 and a beta of 0.04. The business's 50 day moving average price is $8.94 and its two-hundred day moving average price is $13.43.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.36. The business had revenue of $8.75 million for the quarter, compared to the consensus estimate of $10.98 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. Research analysts predict that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.